Skip to content
value.today

Zynerba Pharmeceuticals, Inc.

Formerly AllTranz, Inc.

Total raised
$7 M
1 round on record
Latest round
$7 M
Sep 2014
First round on record
Sep 2014
Today
Private
See the company page

Zynerba Pharmeceuticals, Inc. is listed today as Zynerba Pharmaceuticals: market value, financials and filings are on its company page.

Funding rounds

1 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Zynerba Pharmeceuticals, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Sep 2014$7 MNo. 1$2 to $10 million

Zynerba Pharmeceuticals, Inc.: Raise no. 1, Sep 2014

Investors in this round

30 investors had bought by the notice of Oct 9, 2014: 30 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 1 investor is named for Zynerba Pharmeceuticals, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$7 M of $13 M offered; $6 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Armando Anindo · Executive Officer, Director
  • Suzanne B. Hanlon · Executive Officer
  • Terri B. Sebree · Executive Officer
  • Philip Wagenheim · Director
  • Steven Gailar · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Broadband Capital Management, LLC (CRD 48001) · New York, New YorkSold in CA, CO, CT, FL, MD, NC, NY, PA, SC, WI

Remarks in the notice

  • On fees: “The Placement Agent was reimbursed for expenses incurred in connection with the offering and received cash and stock for services to the company including financial advisory, management consulting and executive recruitment.”
  • On the use of proceeds: “A portion of the proceeds will be used to pay expenses and fees disclosed in Item 15 to the Placement Agent, which is associated with one of the company's directors.”

Signed by Armando Anido, Chairman of the Board and Chief Executive Officer. Newest notice filed Oct 9, 2014. Read the notice at the SEC.

equity, optionsSEC

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Zynerba Pharmeceuticals, Inc. chose not to state its revenue in its newest notice of a funding round (Oct 2014).

    SEC Form D · Oct 2014

  • The industry group it chose in its notices: Pharmaceuticals.

    SEC Form D · Oct 2014

Products and services#

No products or services of Zynerba Pharmeceuticals, Inc. are on record.

Investors#

1 named in official filings. Open an investor to see everything it has backed.

Investors in Zynerba Pharmeceuticals, Inc.
InvestorKindAmountRoundRoleSource
Michael RappPersonnot statednot statedHeld preferred stock, 10% owner (Form 3, 2015)SEC Form 3

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Zynerba Pharmeceuticals, Inc.
NameRoleNamed in
Armando AnindoExecutive officerOct 2014
Suzanne B. HanlonExecutive officerOct 2014
Terri B. SebreeExecutive officerOct 2014
Armando AnindoDirectorOct 2014
Philip WagenheimDirectorOct 2014
Steven GailarDirectorOct 2014

About

Company in Radnor, United States.